Search

PSMA-Targeted Cancer Immunotherapy Patent Granted to Methodist Hospital

The USPTO granted patent US12605446B2 to The Methodist Hospital covering engineered cells with chimeric antigen receptors (CARs) targeting PSMA for prostate cancer treatment. The patent, filed August 20, 2021, contains 15 claims and names Bin He as inventor. This grant confers exclusive IP rights for PSMA-targeted CAR-T immunotherapies in the United States.

FAA Proposes Superseding Airworthiness Directive for Various Helicopters

The FAA proposes to supersede Airworthiness Directive (AD) 2015-20-12, which applies to Sikorsky, Croman Corporation, Carson Helicopters, Robinson Air Crane, Glacier Helicopter, and Siller Helicopters Model helicopters with certain main rotor shaft (MRS) part numbers installed. The proposed AD would retain existing requirements while also establishing retirement lives for each REL MRS, reducing life limits based on a design re-evaluation, and requiring removal of any MRS with oversized dowel pin bores.

Special Conditions Skyryse Robinson R66 Helicopter Fly-by-Wire Flight Control System Annunciation

The FAA proposes special conditions for the Robinson Model R66 helicopter as modified by Skyryse with a digital fly-by-wire flight control system, replacing mechanical flight controls. The existing airworthiness standards under 14 CFR Part 27 do not adequately address this novel design feature, requiring additional safety standards including an annunciation requirement for pilot awareness. Comments are due by June 5, 2026.

Bambini Kids Robot-Assisted Gait Training Safety and Effectiveness Trial in Children With Cerebral Palsy

NIH has registered a clinical trial evaluating the safety and effectiveness of the Bambini Kids pediatric robotic exoskeleton in children with cerebral palsy (CP). The single-arm study will assess robot-assisted gait training (RAGT) as an intervention for gait impairment and motor performance limitations in the pediatric CP population. The trial is registered as NCT07539389 with an estimated completion date of April 20, 2026.

U.S. Military Posture and National Security Challenges in the Indo-Pacific Region

The House Armed Services Committee has scheduled a hearing for April 22, 2026, at 10:00 AM in 2118 Rayburn House Office Building to examine U.S. military posture and national security challenges in the Indo-Pacific region. Three senior defense officials are scheduled to testify: Assistant Secretary of Defense John Noh, Admiral Samuel Paparo of U.S. Indo-Pacific Command, and General Xavier Brunson of United Nations Command/Combined Forces Command/U.S. Forces Korea.

FERC Combined Filings - Electric Corporate, Wholesale Generators, Rate Filings

FERC received multiple electric corporate, exempt wholesale generator, and electric rate filings between April 13-15, 2026. Filings include a Section 203 joint application supplement from AEP Indiana Michigan Transmission Company and Mammoth North LLC, self-certification notices from renewable energy companies, and numerous market-based rate tariff revisions under Section 205(d) from wind, solar, and hydro generators. Comment deadlines range from April 23 to May 6, 2026.

Chimeric Klebicins - Bactoclear Holdings

The USPTO granted US Patent 12,606,598B2 to Bactoclear Holdings PTE, Ltd. covering chimeric klebicins — engineered antimicrobial proteins combining translocation, receptor-binding, and bactericidal domains from different klebicin sources. The patent includes 15 claims and covers compositions, kits, and methods of use designed to improve target cell range and bactericidal activity against bacterial pathogens.

Mr S Pakes v Instant Landscapes Ltd: Employment Tribunal Decision

Employment Tribunal found in favour of Mr S Pakes against Instant Landscapes Ltd in case 3311033/2024. The tribunal determined the respondent breached contract, unfairly dismissed the claimant, and made unlawful deductions from wages. The decision, issued 30 January 2026, constitutes a binding judgment enforceable against the respondent employer.

Nucleic Acid Construct Encoding Chimeric Rhodopsin - Restore Vision

USPTO granted Patent US12606606B2 to Restore Vision Inc. for a nucleic acid construct encoding a chimeric rhodopsin protein combining ion-transporting receptor rhodopsin with G protein-coupled receptor rhodopsin sequences. The patent contains 17 claims classified under C07K peptide chemistry and covers applications for preventing retinal diseases and enhancing visual function.

USPTO Grants JBKLAB Cancer Treatment Patent US12605382B2

The USPTO granted US Patent 12605382B2 to JBKLAB Co., Ltd. for a pharmaceutical composition containing 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenol as an active ingredient, classified under CPC A61P 35/00 for cancer treatment. The patent, filed on May 3, 2022, contains 12 claims and covers the use of the compound alone and in combination with radiotherapy or other anticancer drugs.

Carboxylated Psilocybin Derivatives and Methods of Using (US12605361B2)

USPTO granted patent US12605361B2 to Enveric Biosciences Canada Inc. covering carboxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The patent contains 18 claims and is based on Application No. 18227688 filed July 28, 2023. This grant confers exclusive IP rights to the assignee and does not create compliance obligations for third parties.

Celgene Corp Combination Therapy Patent US12605372B2 Granted

The USPTO granted Patent US12605372B2 to Celgene Corporation on April 21, 2026. The patent covers methods of treating cancers by administering Compound A in combination with daratumumab, or Compound A with daratumumab and dexamethasone. The patent contains 19 claims and derives from Application No. 17983762, filed November 9, 2022.

Recombinant CCN Domain Proteins and Fusion Proteins

USPTO granted Patent US12606602B2 to Oslo University Hospital HF covering recombinant proteins having CCN family thrombospondin type 1 repeat homology domains and fusion proteins combined with fusion partners and linker regions. The patent contains 18 claims and includes novel protease resistant Fc-fragments with applications in oncology.

National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024

The Australian Department of Health, Disability and Ageing has promulgated the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024 under the National Health Act 1953. This legislative instrument establishes the framework for prescribing, supplying, and funding chemotherapy drugs and related pharmaceutical benefits through the PBS. The arrangement applies to approved pharmacists, approved medical practitioners, approved hospital authorities, and TGA-licensed compounders involved in chemotherapy treatment delivery.

ASIC Wins $7M Penalty Against Cigno Australia and BSF Solutions for Credit Act Breaches

The Federal Court of Australia ordered Cigno Australia ($3M), its director Mark Swanepoel ($500K), BSF Solutions ($3M), and its director Brenton Harrison ($500K) to pay a combined $7 million penalty for engaging in credit activity without an Australian Credit Licence and charging prohibited fees. The Court found the No Upfront Charge Loan Model denied consumers protections under the Credit Act including limits on fees and charges. From July 2022 to May 2024, the companies charged consumers over $90 million in fees.

LG Chem Anti-LILRB1 Antibody Patent US12606620B2

The USPTO granted Patent US12606620B2 to LG CHEM, LTD. on April 21, 2026, covering an anti-LILRB1 antibody with increased specificity and its uses in treating cancer. The patent includes 17 claims and covers the antibody or antigen-binding fragments thereof.

High-activity Blood Coagulation Factor XI Mutant Ala570Thr Patent

The USPTO granted patent US12605430B2 to Ruijin Hospital Shanghai Jiaotong University School of Medicine for a high-activity blood coagulation factor XI mutant (Ala570Thr/A570T). The mutant demonstrates resistance to physiological inhibitors after activation and exhibits strong blood coagulation activity. The patent covers nucleotide sequences (SEQ ID NOs: 1-4), amino acid sequence (SEQ ID NO: 5), and applications for treating hemorrhagic diseases through gene therapy, gene editing, and recombinant protein replacement treatments.

CP2c-Targeting Peptide Anticancer Agent Patent Grant

USPTO granted patent US12605453B2 to Industry-University Cooperation Foundation Hanyang University on April 21, 2026, covering a CP2c-targeting peptide-based anticancer agent. The peptide binds to transcription factor CP2c to inhibit the formation of CP2c homotetramers and CP2c/CP2b/PIAS1 heterohexamers, inducing cancer cell-specific cell death. A fatty acid is bound to the peptide for in vivo stability. The patent contains 5 claims.

Letter Agreement for 6.9M Share IPO Among Company, Sponsor, and Insiders

JATT II Acquisition Corp, a Cayman Islands exempted company, entered into a Letter Agreement with sponsor JATT Ventures II L.P. and company insiders on April 16, 2026, governing terms of an underwritten IPO of up to 6,900,000 ordinary shares (including up to 900,000 over-allotment shares). The agreement imposes voting, redemption, and transfer restrictions on the sponsor and insiders, including a 24-month deadline to complete a Business Combination or redeem 100% of the offering shares in cash.

AB Enzymes Xylanase Variants - Patent US12600960B2

The USPTO granted Patent US12600960B2 to AB Enzymes Finland Oy for xylanase variant polypeptides comprising amino acid sequences with at least 79% but less than 100% identity to SEQ ID NO: 1, featuring at least one disulfide bridge and amino acid substitutions at positions 23 and/or 28. The patent covers the variant polypeptide, fusion proteins, enzyme compositions, recombinant host cells for production, and methods of use.

Recombinant AAV Vectors for Treating Parkinson's, MSA, Gaucher's Disease - US12605467B2

USPTO granted patent US12605467B2 to Shanghai Vitalgen Biopharma Co., Ltd. on April 21, 2026, covering recombinant adeno-associated viral (rAAV) vectors encoding aromatic L-amino acid decarboxylase (AADC), glucocerebrosidase (GBA1), and neurotrophic factors (CDNF or GDNF) for treating neurodegenerative disorders including Parkinson's disease, multiple system atrophy, and Gaucher's disease. The patent contains 14 claims and names three inventors.

Effect of Transcutaneous Tibial Nerve Stimulation Combined With Exercise on High Post-Void Residual Urine Volume in Post-Menopausal Women

NIH has registered a clinical trial (NCT07538895) on ClinicalTrials.gov evaluating the effect of transcutaneous tibial nerve stimulation combined with exercise on high post-void residual urine volume in post-menopausal women. The randomized study will enroll 60 participants across two groups over 12-week physiotherapy sessions. This is an informational study registration with no compliance or reporting obligations.

DENV4 NS1 Antibody Patent US12606611B2 Granted to US Dept Health

The USPTO granted Patent No. US12606611B2 to the United States of America, as represented by the Secretary of the Department of Health & Human Services, covering antibodies that specifically bind to Dengue virus serotype 4 (DENV4) non-structural protein 1 (NS1). The patent includes 16 claims and names Elizabeth Anne Hunsperger and Tesfaye Gelanew Taye as inventors.

Polymers for Hyperuricemia Treatment Granted to Waterstone

The USPTO granted patent US12605401B2 to Waterstone Pharmaceuticals (Wuhan) Co., Ltd. covering polymers and compositions for binding uric acid and treating hyperuricemia, gout, and related diseases. The patent, with 20 claims, was filed on May 18, 2022 under Application No. 17747006 and lists eight inventors.

Netherton Syndrome LEKTI Microbe Patent - Azitra Inc

The USPTO granted US Patent 12606610B2 to Azitra Inc covering engineered microbes expressing recombinant LEKTI domains for the treatment of Netherton Syndrome. The patent contains 15 claims spanning compositions, methods, and kits. Inventors are Travis Michael Whitfill and Azim Momin Munivar.

NCT07535723: Botulinum Toxin and GON Block for Chronic Migraine

A new randomized controlled trial (NCT07535723) was registered on ClinicalTrials.gov evaluating the combination of OnabotulinumtoxinA (Botox) injections with Greater Occipital Nerve (GON) block versus single therapy for chronic migraine patients. The trial will assess improvements in headache frequency, severity, and quality of life. Enrollment target and sponsor details were not specified in the registration record.

Ivonescimab With Dato-DXd or Osimertinib Phase 1

NIH ClinicalTrials.gov registered Phase 1 trial NCT07535437 evaluating ivonescimab in combination with Dato-DXd or osimertinib for treatment of EGFR-mutated non-small cell lung cancer. The dose-escalation study will assess safety and tolerability to determine optimal dosing. Participants with NSCLC harboring EGFR mutations will receive fixed-dose ivonescimab with escalating doses of either Dato-DXd or osimertinib.

Multibank MHCs Draw Fresh Attention in Banking

The ABA Banking Journal reports that multibank mutual holding companies (MHCs) are gaining attention as mutual banks seek scale while preserving local identity. Fewer than a dozen exist nationwide per FDIC data, yet recent mergers suggest the model is quietly rising. First Mutual Holding Co. in Lakewood, Ohio, which formed in 2015, now has five mutual banks under its umbrella with $3.3 billion of total assets and has seen combined noninterest expense fall from 3% of assets pre-pandemic to 2.1% today.

New Mexico DOJ Arrests Human Trafficker Preying on Minor

The New Mexico Department of Justice announced the arrest of Pete Guevara on charges of human trafficking and trafficking controlled substances. Guevara is accused of exploiting a 17-year-old runaway minor to sell narcotics. The investigation was initiated following a tip from a family advocacy group.

Texas Doctor Charged with Illegal Opioid Distribution

The DOJ announced an indictment unsealed in the Southern District of Texas charging Dr. James Robles, 70, with operating a cash-only Houston clinic used to illegally distribute controlled substances. Over approximately four years, Robles allegedly prescribed 2.9 million hydrocodone pills, 1.3 million oxycodone pills, and 1.1 million carisoprodol pills, generating over $2 million in cash deposits. He faces three counts including conspiracy to distribute controlled substances, distribution of controlled substances, and maintaining drug-involved premises, each carrying a maximum penalty of 20 years imprisonment.

Adriatic Plumbing v. WA Dept of Labor & Industries - Trainee Supervision Violation

The Washington Court of Appeals, Division II affirmed an administrative law judge's ruling upholding a Department of Labor and Industries (L&I) infraction against Adriatic Plumbing. L&I cited the company for violating RCW 18.106.070's requirement that trainee plumbers be supervised by journeyman plumbers at a maximum ratio of one trainee per journeyman on any jobsite. The court rejected Adriatic Plumbing's arguments that the evidence was insufficient and the ruling was arbitrary and capricious, finding substantial evidence supported the infraction.

Petersen Energía v. Argentina - Securities Expropriation

The Second Circuit decided consolidated cases involving Petersen Energía and Eton Park Capital Management as minority shareholders of YPF S.A. against Argentina and YPF S.A. The court affirmed in part and reversed in part the SDNY judgment stemming from Argentina's expropriation of oil company shares, held that breach of contract damages claims are not cognizable under Argentine law, and remanded for further proceedings. The district court had entered judgment awarding $16.1 billion in damages.

Petersen Energía v. Argentine Republic - Shareholder Expropriation

The Second Circuit affirmed in part and reversed in part the $16.1 billion judgment against Argentina in favor of Petersen Energía and Eton Park Capital Management minority shareholders of YPF S.A. The court held that breach of contract damages claims against Argentina and YPF are not cognizable under Argentine law, reversing that portion of the judgment. The case has been remanded to the Southern District of New York for further proceedings.

SEC Form N-14 Information Collection Extension Request

The SEC has submitted a request to the OMB for an extension of the information collection requirements for Form N-14. This form is used by management investment companies and business development companies for securities registration in business combination transactions. The SEC estimates the annual burden to be approximately 103,685 hours and $3,401,800.

Additional MRI Monitoring Recommendation for Leqembi Patients

FDA issued a Drug Safety Communication recommending additional MRI monitoring for patients taking Leqembi (lecanemab). The agency is requiring updated prescribing information to include MRI monitoring between the 2nd and 3rd infusion, earlier than the current recommendation for MRI before the 5th infusion. This change aims to identify amyloid-related imaging abnormalities with edema (ARIA-E) earlier to prevent serious and potentially fatal events.

Three Public Companies Fined for Failing to Lodge Financial Reports

ASIC announced that three ASX-listed public companies were convicted and fined a combined $1,170,000 at Downing Centre Local Court on 17 March 2026 for failing to lodge annual financial reports with ASIC. The convictions involved Urban Ecological Systems Limited ($240,000), Invitrocue Limited ($530,000), and Boyuan Holdings Limited ($400,000). This enforcement action aligns with ASIC's stated 2026 focus on non-lodgement of financial reports.

USITC Institutes Section 337 Investigation of Laptops, Routers, Gateways

The U.S. International Trade Commission (USITC) has instituted a Section 337 investigation into alleged patent infringement by certain laptops, routers, gateways, and components imported into the U.S. The investigation names ASUSTeK Computer Inc., ASUS Computer International, Inc., TP-Link Systems Inc., D-Link Corporation, D-Link Systems, Inc., and Ubiquiti Inc. as respondents.

Ohio AG Sues Contractors for $564K Defrauding Consumers

Ohio Attorney General Dave Yost has filed four lawsuits against home-improvement contractors and a builder of outdoor structures, alleging they defrauded consumers of a combined $564,000. The lawsuits cite violations of the Ohio Consumer Sales Practices Act and, in one case, the Home Solicitation Sales Act.

Sanjeev Kumar Sentenced, Abdul Hussin Ahmadbin Pleads Guilty to Fraud

The Iowa Insurance Division announced that Sanjeev Kumar was sentenced to up to 25 years for his role in a fraud operation targeting a senior citizen. Abdul Hussin Ahmadbin also pleaded guilty to related charges. The case highlights successful inter-agency cooperation in combating financial exploitation.

EDPB Opinion on Dutch Authority's IBM Group BCR Draft Decision

The European Data Protection Board (EDPB) has issued an opinion on a draft decision by the Dutch Data Protection Authority concerning the Binding Corporate Rules (BCRs) of the IBM Group. This opinion addresses the international transfer of data and the adequacy of IBM's BCRs.